TNDMNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
TANDEM DIABETES CARE INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$16.38+0.14 (+0.86%)
Close on Oct 19, 2026
- Market cap
- $1.13B
- P/E (TTM)
- –
- Dividend yield
- –
TANDEM DIABETES CARE INC revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Supplies and other | $566.17M | $555.07M | $550.60M | $528.48M | $517.48M | $502.55M | $475.79M | $465.46M | $443.14M | $425.81M | $406.98M | – | 54.4% | +9.4% |
| Pump | $475.23M | $472.45M | $464.14M | $448.29M | $452.98M | $448.98M | $434.17M | $401.39M | $374.63M | $368.43M | $365.84M | – | 45.6% | +4.9% |
| Net sales recognized (deferred) for Tandem Choice program | – | – | $0 | $30.20M | $31.24M | $31.40M | $30.25M | – | – | – | – | – | – | – |
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $726.23M | $717.15M | $706.94M | $711.04M | $707.05M | $693.56M | $672.69M | $609.04M | $567.61M | $553.40M | $554.88M | $569.75M | 69.7% | +2.7% |
| International | $315.19M | $310.39M | $307.80M | $295.97M | $294.67M | $289.40M | $267.52M | $245.32M | $228.39M | $216.61M | $192.84M | $201.68M | 30.3% | +7.0% |
From the segment and revenue-disaggregation notes of Tandem Diabetes Care's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.